Index RUT
P/E 11.60
EPS (ttm) 2.07
Insider Own 1.47%
Shs Outstand 166.98M
Perf Week -8.15%
Market Cap 4.01B
Forward P/E 9.40
EPS next Y 2.56
Insider Trans -0.63%
Shs Float 164.62M
Perf Month -12.79%
Income 355.76M
PEG 0.47
EPS next Q 0.62
Inst Own 106.39%
Short Float 8.71%
Perf Quarter -13.29%
Sales 1.66B
P/S 2.41
EPS this Y 85.76%
Inst Trans -1.28%
Short Ratio 7.32
Perf Half Y -7.86%
Book/sh 7.20
P/B 3.33
EPS next Y -4.48%
ROA 19.68%
Short Interest 14.34M
Perf Year -12.27%
Cash/sh 4.63
P/C 5.19
EPS next 5Y 24.80%
ROE 35.93%
52W Range 20.46 - 32.88
Perf YTD -13.45%
Dividend Est. -
P/FCF 11.35
EPS past 5Y -
ROI 22.72%
52W High -26.98%
Beta 0.62
Dividend TTM -
Quick Ratio 2.50
Sales past 5Y 10.61%
Gross Margin 82.17%
52W Low 17.35%
ATR (14) 0.84
Dividend Ex-Date -
Current Ratio 2.86
EPS Y/Y TTM 320.93%
Oper. Margin 17.44%
RSI (14) 30.16
Volatility 3.67% 2.87%
Employees 2100
Debt/Eq 0.31
Sales Y/Y TTM 49.61%
Profit Margin 21.39%
Recom 2.15
Target Price 35.58
Option/Short Yes / Yes
LT Debt/Eq 0.30
EPS Q/Q 485.63%
Payout 0.00%
Rel Volume 1.15
Prev Close 23.77
Sales Surprise 4.21%
EPS Surprise -50.83%
Sales Q/Q 23.89%
Earnings May 01 BMO
Avg Volume 1.96M
Price 24.01
SMA20 -8.77%
SMA50 -13.94%
SMA200 -10.46%
Trades
Volume 2,254,805
Change 1.01%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-19-24 Initiated
Robert W. Baird
Outperform
$37
Feb-20-24 Downgrade
UBS
Neutral → Sell
$25
Nov-20-23 Resumed
JP Morgan
Neutral
$33
Oct-24-23 Upgrade
Evercore ISI
In-line → Outperform
Oct-17-23 Initiated
UBS
Neutral
$31
Nov-03-22 Upgrade
Piper Sandler
Neutral → Overweight
$26 → $30
Oct-14-22 Upgrade
BofA Securities
Underperform → Neutral
$27 → $25
Aug-16-22 Initiated
Piper Sandler
Neutral
$26
Apr-22-22 Resumed
Goldman
Buy
$35
Apr-20-22 Initiated
Goldman
Buy
$35
Jan-27-22 Upgrade
Cantor Fitzgerald
Hold → Overweight
$32
Dec-01-21 Initiated
Citigroup
Neutral
$22
Oct-07-21 Upgrade
Jefferies
Hold → Buy
$36
Sep-02-21 Downgrade
BofA Securities
Neutral → Underperform
$27
Oct-15-20 Upgrade
Mizuho
Neutral → Buy
$19 → $24
Jul-30-20 Downgrade
Goldman
Neutral → Sell
$19 → $15
Feb-14-20 Reiterated
H.C. Wainwright
Neutral
$26 → $25
Feb-14-20 Downgrade
JP Morgan
Overweight → Neutral
$21
Feb-14-20 Downgrade
BofA/Merrill
Buy → Neutral
$31 → $20
Feb-06-20 Initiated
Mizuho
Neutral
Show Previous Ratings
Apr-17-24 04:00PM
10:01AM
Apr-11-24 02:18PM
(Investor's Business Daily)
10:15AM
10:00AM
09:45AM
Loading…
Apr-10-24 09:45AM
Apr-09-24 12:38PM
(Associated Press Finance)
07:00AM
Apr-08-24 07:00AM
Apr-02-24 12:10PM
Mar-18-24 07:01PM
Mar-15-24 06:15PM
Mar-13-24 12:45PM
Mar-12-24 09:50AM
Mar-10-24 10:00AM
09:45AM
Loading…
Mar-08-24 09:45AM
Mar-07-24 06:15PM
07:00AM
Feb-29-24 06:15PM
Feb-23-24 09:50AM
Feb-21-24 09:45AM
Feb-16-24 10:18AM
Feb-15-24 02:40PM
(Investor's Business Daily) +16.33%
01:34PM
09:30AM
07:37AM
07:30AM
(Associated Press Finance)
07:00AM
Feb-12-24 09:16AM
Feb-08-24 04:10PM
04:00PM
Loading…
04:00PM
10:00AM
Feb-07-24 06:15PM
Feb-02-24 02:15AM
Feb-01-24 06:15PM
05:00PM
Jan-30-24 12:10PM
Jan-26-24 06:15PM
Jan-15-24 04:51PM
Jan-12-24 06:15PM
Jan-03-24 04:00PM
07:00AM
Dec-27-23 11:45AM
Dec-22-23 06:15PM
Dec-20-23 02:15PM
12:15PM
Dec-18-23 01:45PM
Dec-14-23 10:45AM
06:05AM
Dec-13-23 04:08AM
Dec-11-23 02:30PM
Dec-01-23 06:16PM
Nov-29-23 03:15PM
Nov-24-23 11:31AM
Nov-21-23 04:00PM
11:45AM
Nov-20-23 01:45PM
Nov-16-23 10:30AM
Nov-15-23 08:57AM
07:15AM
07:00AM
Nov-14-23 01:45PM
10:33AM
05:50AM
Nov-13-23 09:50PM
12:45PM
Nov-10-23 03:00PM
Nov-09-23 11:12AM
Nov-08-23 11:30AM
Nov-07-23 04:00PM
Nov-04-23 12:16PM
Oct-31-23 05:08PM
01:30PM
Oct-26-23 12:00PM
10:37AM
Oct-25-23 12:38PM
09:30AM
07:23AM
(Associated Press Finance)
07:00AM
Oct-24-23 09:51AM
Oct-23-23 04:00PM
(Investor's Business Daily) -9.59%
02:00PM
08:00AM
Oct-19-23 10:01AM
Oct-18-23 06:15PM
04:00PM
Oct-16-23 12:30PM
Oct-13-23 10:45AM
Oct-11-23 12:00PM
Oct-10-23 05:00PM
07:00AM
Sep-21-23 01:00PM
Sep-19-23 11:05AM
Sep-18-23 01:15PM
Sep-15-23 06:15PM
Sep-13-23 10:50AM
Sep-11-23 07:00AM
Sep-08-23 06:15PM
Sep-07-23 03:15PM
11:31AM
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Nichols Christian Todd SVP, Chief Commercial Officer Mar 18 '24 Sale 28.10 10,417 292,740 65,911 Mar 18 04:02 PM Parisi Samuel Joseph VP, Finance (Interim PAO) Feb 27 '24 Sale 29.65 2,559 75,874 7,717 Feb 27 04:09 PM LAURENCIN CATO T Director Feb 15 '24 Option Exercise 22.52 2,690 60,579 17,859 Feb 16 04:01 PM LAURENCIN CATO T Director Feb 15 '24 Sale 31.85 2,690 85,676 15,169 Feb 16 04:01 PM LAURENCIN CATO T Director Jun 08 '23 Option Exercise 22.97 2,638 60,595 10,117 Jun 08 04:31 PM LAURENCIN CATO T Director Jun 08 '23 Sale 31.85 2,638 84,020 7,479 Jun 08 04:31 PM LAURENCIN CATO T Director Jun 07 '23 Option Exercise 22.97 2,800 64,316 10,279 Jun 07 05:12 PM LAURENCIN CATO T Director Jun 07 '23 Sale 31.50 2,800 88,200 7,479 Jun 07 05:12 PM Nichols Christian Todd SVP, Chief Commercial Officer May 30 '23 Option Exercise 20.43 19,634 401,123 68,118 May 30 08:16 PM Nichols Christian Todd SVP, Chief Commercial Officer May 30 '23 Sale 28.93 27,134 784,862 40,984 May 30 08:16 PM Wysenski Nancy Director May 09 '23 Option Exercise 31.13 41,250 1,284,112 57,079 May 10 04:34 PM Wysenski Nancy Director May 09 '23 Sale 31.24 41,250 1,288,786 15,829 May 10 04:34 PM
Index NDX, S&P 500
P/E 47.52
EPS (ttm) 10.06
Insider Own 0.99%
Shs Outstand 83.03M
Perf Week -5.14%
Market Cap 39.74B
Forward P/E 37.40
EPS next Y 12.79
Insider Trans -8.03%
Shs Float 82.27M
Perf Month -9.73%
Income 845.04M
PEG 3.96
EPS next Q 2.70
Inst Own 90.04%
Short Float 2.13%
Perf Quarter -7.22%
Sales 3.66B
P/S 10.85
EPS this Y 11.13%
Inst Trans -0.23%
Short Ratio 4.19
Perf Half Y 11.34%
Book/sh 17.88
P/B 26.75
EPS next Y 14.38%
ROA 28.14%
Short Interest 1.76M
Perf Year -0.68%
Cash/sh 5.46
P/C 87.54
EPS next 5Y 12.00%
ROE 80.74%
52W Range 372.50 - 583.39
Perf YTD -13.84%
Dividend Est. -
P/FCF 51.41
EPS past 5Y 18.76%
ROI 38.29%
52W High -18.02%
Beta 1.27
Dividend TTM -
Quick Ratio 1.11
Sales past 5Y 10.69%
Gross Margin 59.73%
52W Low 28.39%
ATR (14) 11.47
Dividend Ex-Date -
Current Ratio 1.51
EPS Y/Y TTM 25.28%
Oper. Margin 29.88%
RSI (14) 21.31
Volatility 2.13% 1.97%
Employees 11000
Debt/Eq 0.72
Sales Y/Y TTM 8.72%
Profit Margin 23.08%
Recom 2.31
Target Price 620.56
Option/Short Yes / Yes
LT Debt/Eq 0.49
EPS Q/Q 12.80%
Payout 0.00%
Rel Volume 1.27
Prev Close 489.57
Sales Surprise 1.09%
EPS Surprise 9.22%
Sales Q/Q 8.81%
Earnings May 01 BMO
Avg Volume 418.62K
Price 478.24
SMA20 -8.05%
SMA50 -12.19%
SMA200 -5.27%
Trades
Volume 533,178
Change -2.31%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-24 Downgrade
Piper Sandler
Overweight → Neutral
$525
Dec-07-23 Initiated
Exane BNP Paribas
Outperform
$602
Dec-04-23 Upgrade
Cleveland Research
Neutral → Buy
Aug-02-23 Downgrade
Atlantic Equities
Overweight → Neutral
$610
Jul-25-22 Downgrade
Stifel
Buy → Hold
$415
Jul-21-22 Upgrade
Goldman
Neutral → Buy
$530 → $435
Jul-12-22 Initiated
Piper Sandler
Overweight
$440
May-05-22 Downgrade
BofA Securities
Buy → Neutral
$550 → $470
Feb-08-22 Initiated
Atlantic Equities
Overweight
$650
Nov-18-21 Initiated
Morgan Stanley
Overweight
Aug-05-21 Resumed
Credit Suisse
Outperform
$735
Jul-12-21 Downgrade
Guggenheim
Buy → Neutral
Feb-17-21 Initiated
Barclays
Overweight
$600
Sep-09-19 Initiated
Goldman
Neutral
$277
May-23-19 Initiated
Guggenheim
Buy
$276
Nov-02-18 Reiterated
BofA/Merrill
Buy
$275 → $235
May-07-18 Reiterated
Stifel
Buy
$215 → $225
Jan-16-18 Initiated
Piper Jaffray
Overweight
$200
Aug-23-17 Upgrade
BofA/Merrill
Neutral → Buy
Jul-28-17 Upgrade
CL King
Neutral → Buy
Show Previous Ratings
Apr-09-24 06:00PM
12:00PM
Apr-05-24 12:10PM
Apr-04-24 04:30PM
Apr-02-24 08:31AM
02:15AM
Loading…
Mar-29-24 02:15AM
Mar-21-24 05:42AM
Mar-08-24 03:01AM
Mar-06-24 11:30AM
Mar-05-24 03:05AM
Feb-22-24 03:46AM
Feb-20-24 02:00PM
Feb-18-24 01:26PM
Feb-16-24 12:56PM
Feb-15-24 11:53AM
07:00AM
Loading…
07:00AM
Feb-10-24 02:07AM
Feb-09-24 03:35PM
Feb-08-24 10:34AM
Feb-06-24 02:25PM
(Investor's Business Daily)
08:46AM
02:05AM
(Thomson Reuters StreetEvents)
Feb-05-24 10:31PM
(Morningstar Research) +8.53%
10:37AM
09:30AM
07:45AM
07:40AM
06:53AM
06:39AM
(Associated Press Finance)
06:30AM
08:46AM
Loading…
Feb-02-24 08:46AM
Jan-31-24 09:15AM
07:29AM
Jan-30-24 12:10PM
Jan-29-24 11:58AM
Jan-25-24 07:18AM
Jan-23-24 03:30PM
Jan-19-24 07:14AM
Jan-15-24 11:33AM
Jan-12-24 07:05AM
07:00AM
Jan-11-24 09:48PM
Dec-18-23 07:40AM
05:19AM
Dec-09-23 01:05AM
Dec-07-23 09:16PM
04:15PM
Dec-06-23 03:25PM
(Investor's Business Daily)
Dec-04-23 08:12PM
(Morningstar Research) +7.05%
Dec-01-23 11:31AM
Nov-16-23 09:28AM
Nov-13-23 06:10AM
Nov-11-23 12:00PM
Nov-09-23 07:48AM
Nov-08-23 07:00AM
Nov-02-23 06:55PM
08:52AM
01:10AM
12:45AM
(Thomson Reuters StreetEvents)
Nov-01-23 10:00PM
02:52PM
09:53AM
09:28AM
08:46AM
06:40AM
(Associated Press Finance)
06:30AM
Oct-31-23 11:25AM
Oct-25-23 10:02AM
Oct-23-23 06:19AM
Oct-13-23 11:40AM
Oct-06-23 07:30AM
Oct-05-23 04:00PM
Sep-28-23 10:12AM
Sep-19-23 01:08PM
Sep-13-23 07:39PM
Sep-08-23 12:04PM
Sep-06-23 11:14AM
Aug-31-23 11:31AM
07:14AM
04:35AM
Aug-29-23 12:06PM
11:35AM
Aug-27-23 08:44AM
Aug-25-23 04:30AM
(Zacks Small Cap Research)
Aug-23-23 09:26AM
Aug-18-23 11:04AM
Aug-13-23 07:00AM
Aug-08-23 07:01AM
Aug-05-23 09:15AM
Aug-03-23 09:01AM
Aug-02-23 02:06PM
Aug-01-23 10:20PM
(Thomson Reuters StreetEvents)
05:27PM
11:30AM
11:02AM
08:46AM
07:45AM
06:37AM
06:30AM
Jul-27-23 10:00AM
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
POLEWACZYK JAMES F Executive Vice President Mar 06 '24 Option Exercise 422.45 8,104 3,423,547 18,815 Mar 07 05:00 PM POLEWACZYK JAMES F Executive Vice President Mar 06 '24 Sale 558.44 8,104 4,525,596 10,711 Mar 07 05:00 PM Vandebroek Sophie V. Director Mar 05 '24 Option Exercise 245.79 1,404 345,089 2,620 Mar 07 05:00 PM Vandebroek Sophie V. Director Mar 05 '24 Sale 562.98 1,404 790,427 1,216 Mar 07 05:00 PM MAZELSKY JONATHAN JAY President and CEO Feb 21 '24 Option Exercise 206.94 483 99,952 82,047 Feb 22 05:02 PM Underberg Sharon E. EVP, GC & Corporate Secretary Feb 16 '24 Option Exercise 206.94 483 99,952 5,595 Feb 20 05:01 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 15 '24 Option Exercise 206.94 483 99,952 30,835 Feb 20 05:00 PM Smith Martin Alexander Executive Vice President Feb 14 '24 Option Exercise 0.00 337 0 583 Feb 16 05:58 PM Schreck Michael Executive Vice President Feb 14 '24 Option Exercise 0.00 368 0 903 Feb 16 05:58 PM Johnson Michael Perkins EVP and CHRO Feb 14 '24 Option Exercise 0.00 176 0 243 Feb 16 05:56 PM Lane Michael Executive Vice President Feb 14 '24 Option Exercise 0.00 939 0 6,726 Feb 16 05:56 PM MAZELSKY JONATHAN JAY President and CEO Feb 14 '24 Option Exercise 0.00 4,156 0 83,403 Feb 16 05:56 PM Erickson Michael G Executive Vice President Feb 14 '24 Option Exercise 0.00 462 0 10,801 Feb 16 05:54 PM FENNELL GEORGE SVP, Chief Revenue Officer Feb 14 '24 Option Exercise 0.00 370 0 7,082 Feb 16 05:55 PM Hunt Nimrata Executive Vice President Feb 14 '24 Option Exercise 0.00 664 0 11,731 Feb 16 05:55 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 14 '24 Option Exercise 0.00 1,731 0 31,449 Feb 16 05:57 PM POLEWACZYK JAMES F Executive Vice President Feb 14 '24 Option Exercise 0.00 927 0 10,990 Feb 16 05:57 PM FENNELL GEORGE SVP, Chief Revenue Officer Feb 08 '24 Option Exercise 62.00 9,810 608,220 14,910 Feb 09 05:03 PM FENNELL GEORGE SVP, Chief Revenue Officer Feb 08 '24 Sale 573.87 8,198 4,704,559 6,712 Feb 09 05:03 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 07 '24 Option Exercise 141.60 23,326 3,302,962 53,044 Feb 09 05:01 PM MAZELSKY JONATHAN JAY President and CEO Feb 07 '24 Option Exercise 67.85 12,000 814,200 91,247 Feb 09 05:00 PM MCKEON BRIAN P EVP, CFO and Treasurer Feb 07 '24 Sale 570.01 23,326 13,295,975 29,718 Feb 09 05:01 PM MAZELSKY JONATHAN JAY President and CEO Feb 07 '24 Sale 572.61 12,000 6,871,319 79,247 Feb 09 05:00 PM POLEWACZYK JAMES F Executive Vice President Dec 07 '23 Option Exercise 253.92 11,636 2,954,645 21,686 Dec 08 05:00 PM POLEWACZYK JAMES F Executive Vice President Dec 07 '23 Sale 521.79 11,636 6,071,500 10,050 Dec 08 05:00 PM MAZELSKY JONATHAN JAY President and CEO Dec 04 '23 Option Exercise 79.54 13,424 1,067,745 86,361 Dec 06 05:01 PM MAZELSKY JONATHAN JAY President and CEO Dec 04 '23 Sale 513.05 7,128 3,657,049 79,233 Dec 06 05:01 PM Lane Michael Executive Vice President Nov 07 '23 Option Exercise 133.76 1,728 231,142 5,774 Nov 08 05:09 PM Smith Martin Alexander Executive Vice President Sep 01 '23 Option Exercise 0.00 19 0 226 Sep 06 05:01 PM MAZELSKY JONATHAN JAY President and CEO Aug 31 '23 Option Exercise 79.54 13,424 1,067,745 86,349 Sep 05 05:01 PM MAZELSKY JONATHAN JAY President and CEO Aug 31 '23 Sale 512.01 13,424 6,873,267 72,925 Sep 05 05:01 PM POLEWACZYK JAMES F Executive Vice President Aug 29 '23 Option Exercise 144.21 16,909 2,438,478 32,947 Aug 31 05:17 PM POLEWACZYK JAMES F Executive Vice President Aug 29 '23 Sale 510.56 22,909 11,696,446 10,038 Aug 31 05:17 PM MAZELSKY JONATHAN JAY President and CEO Aug 05 '23 Option Exercise 0.00 384 0 73,095 Aug 08 05:59 PM MCKEON BRIAN P EVP, CFO and Treasurer Aug 05 '23 Option Exercise 0.00 192 0 29,809 Aug 08 05:59 PM Lane Michael Executive Vice President Aug 03 '23 Option Exercise 187.47 16,027 3,004,598 20,061 Aug 07 05:04 PM Lane Michael Executive Vice President Aug 03 '23 Sale 510.00 16,027 8,173,770 4,034 Aug 07 05:04 PM AYERS JONATHAN W Director May 19 '23 Option Exercise 79.54 10,000 795,400 147,039 May 22 05:00 PM AYERS JONATHAN W Director May 19 '23 Sale 491.35 10,000 4,913,502 137,039 May 22 05:00 PM AYERS JONATHAN W Director May 18 '23 Option Exercise 79.54 10,000 795,400 147,039 May 22 05:00 PM AYERS JONATHAN W Director May 18 '23 Sale 489.23 10,000 4,892,268 137,039 May 22 05:00 PM Vandebroek Sophie V. Director May 11 '23 Option Exercise 0.00 344 0 1,216 May 15 05:32 PM COLLINS Asha Director May 11 '23 Option Exercise 0.00 344 0 522 May 15 05:31 PM ESSIG STUART Director May 11 '23 Option Exercise 0.00 344 0 1,717 May 15 05:31 PM Kingsley Lawrence D Director May 11 '23 Option Exercise 0.00 464 0 8,544 May 15 05:32 PM SZOSTAK M ANNE Director May 11 '23 Option Exercise 0.00 344 0 1,604 May 15 05:32 PM AYERS JONATHAN W Director May 11 '23 Option Exercise 0.00 344 0 140,553 May 15 05:31 PM AYERS JONATHAN W Director May 10 '23 Option Exercise 178.26 560 99,826 141,894 May 11 05:01 PM Underberg Sharon E. EVP, GC & Corporate Secretary May 05 '23 Option Exercise 206.94 483 99,952 4,245 May 08 05:04 PM MCKEON BRIAN P EVP, CFO and Treasurer May 05 '23 Option Exercise 178.26 560 99,826 29,605 May 08 05:02 PM SZOSTAK M ANNE Director May 05 '23 Sale 474.89 2,000 949,789 4,700 May 08 05:03 PM Lane Michael Executive Vice President May 05 '23 Sale 484.00 1,000 484,000 4,022 May 08 05:01 PM Vandebroek Sophie V. Director May 04 '23 Option Exercise 206.62 2,187 451,878 3,059 May 05 06:01 PM MAZELSKY JONATHAN JAY President and CEO May 04 '23 Option Exercise 178.26 560 99,826 73,301 May 05 06:00 PM Vandebroek Sophie V. Director May 04 '23 Sale 469.02 2,187 1,025,740 872 May 05 06:01 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite